

DR JYOTI NANGALIA

Email: jn218@cam.ac.uk ; jn5@sanger.ac.uk

Qualifications

2016	PhD	University of Cambridge
2010	FRCPATH	London
2006	MRCP	London
2005	MA	University of Cambridge
2003	MB BChir	University of Cambridge
2001	BA	University of Cambridge (St John's College)

Secondary Education

1998 King Henry VIII School, Coventry

Prizes and Distinctions

2015-16	European & American Societies of Haematology 'Translational Research Training in Hematology' Fellow 2016-2017.
2015	Best Speaker Prize, Association of Physicians of Great Britain and Ireland, 2015
2014	Johnstone & Florence Stoney Prize, British Federation of Women Graduates 2014
2003	Roger Morris Prize for Surgery, Lewin Prize for Surgery, University of Cambridge
2003	Distinctions in all medical final examinations, University of Cambridge
1999-2003	College and Wright Prizes, Rolleston Scholar of St John's College, University of Cambridge

Grant awards

2016	Cancer Research UK Clinician Scientist Fellowship (23917): Evolutionary dynamics of the cancer epigenome in myeloproliferative neoplasms.
2016	European Haematology Association Advanced Non-Clinical Fellowship.
2014	Bloodwise Project Grant Award (14021): Molecular characterisation of essential thrombocythaemia patients in the PT1 trial.
2014	British Federation of Women Graduates Award
2011	Kay Kendall Junior Clinical Fellowship

Current Employment

Feb 2019-current	Consultant Haematologist, Addenbrookes Hospital
Feb 201-current	Cancer Research UK Clinician Scientist, Wellcome Trust Sanger Institute, Hinxton

Publications (first author)

-[Nangalia J](#), Mitchell E, Green AR. Clonal approaches to understanding the impact of mutations on hematological disease development. **Blood**. Accepted.

-Grinfeld J*, [Nangalia J*](#), Baxter EJ...Green AR*, Campbell PJ*. Disease heterogeneity and personalized prognosis in myeloproliferative neoplasms, **N Engl J Med**. 2018 Oct 11;379(15):1416-1430.

-[Nangalia J](#), Green AR. Myeloproliferative neoplasms: from origins to outcomes. **Hematology Am Soc Hematol Educ Program**. 2017 Dec 8;2017(1):470-479.

-[Nangalia J](#), Green AR. Myeloproliferative neoplasms: from origins to outcomes. **Blood**. 2017 Dec 7;130(23):2475-2483.

-Grinfeld J, [Nangalia J](#), Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. **Haematologica**. 2017 Jan;102(1):7-17

-[Nangalia J](#) and Green AR. Pathogenesis of Myeloproliferative Disorders. **Annu Rev Pathol**. 2016 May 23;11:101-26

-[Nangalia J](#) and Green AR. The evolving genomic landscape of myeloproliferative neoplasms. **Hematology Am Soc Hematol Educ Program**. 2014 Dec 5;2014(1):287-96

-[Nangalia J](#), Nice FL, Wedge DC... Green AR. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. **Haematologica**. 2015 Nov;100(11)

-Guglielmelli P*, [Nangalia J*](#), Green AR*, Vannucchi AM*. CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. **Am J Hematol**. 2014 May;89(5):453-6.

-Kollmann K*, [Nangalia J*](#), Warsch W*...Green AR. MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. **Leukemia**. 2014 Sep 24

-[Nangalia J*](#), Massie CE*, ...Campbell PJ*, Green AR*. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. **N Engl J Med**. 2013 Dec 19;369(25):2391-405.

-[Nangalia J](#), Smith H, Wimperis JZ. Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not

require growth factor support. **Leuk Lymphoma**. 2008 Aug;49(8):1530-6.

Publications (coauthor selected)

- McMullin MF, Harrison CN, ... Nangalia J...Mead AJ; BSH Committee. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. **Br J Haematol**. 2019 Jan;184(2):176-191.
- McMullin MFF, Mead AJ... Nangalia J... Harrison CN; A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. British Society for Haematology Guideline. **Br J Haematol**. 2019 Jan;184(2):161-175.
- Godfrey AL, Campbell PJ...Nangalia J...Harrison CN; Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. **J Clin Oncol**. 2018 Aug 28;JCO2018788414.
- Mesa RA, Vannucchi AM... Nangalia J... Harrison CN. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. **Lancet Haematol**. 2017 May;4(5)
- Chen E, Ahn JS, Sykes DB... Nangalia J... Mullally A.RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. **Cell Rep**. 2015 Dec 22
- Malherbe JA, Fuller KA... Nangalia J... Erber WN. Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms. **J Clin Pathol**. 2015 Aug 19
- Ortmann CA*, Kent DG*, Nangalia J... Green AR. Effect of mutation order on myeloproliferative neoplasms. **N Engl J Med**. 2015 Feb 12;372(7):601-12.
- Ju YS, Tubio JM, Mifsud W... Nangalia J... Stratton MR. Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. **Genome Res**. 2015 May 11
- Tapper W, Jones AV, Kralovics R... Nangalia J... Cross NC. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. **Nat Commun**. 2015 Apr 7;6:6691
- Jones AV, Ward D, Lyon M...Nangalia J... Cross NC. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. **Leuk Res**. 2015 Jan;39(1):82-7.
- Godfrey AL, Nangalia J, Baxter EJ... Green AR. Non-genetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera? **Blood**. 2014 Nov 20;124(22):3332-4.
- Chen E, Ahn JS, Massie CE... Nangalia J... Green AR. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. **Proc Natl Acad Sci U S A**. 2014 Oct 21;111(42):15190-5.
- Ju YS, Alexandrov LB, Gerstung M... Nangalia J...Campbell PJ. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. **Elife**. 2014 Oct 1;3
- Li J, Kent DG, Godfrey AL... Nangalia J...Green AR. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. **Blood**. 2014 May 15;123(20):3139-51.
- Wong CC, Martincorena I... Nangalia J...Adams DJ. Inactivating CUX1 mutations promote tumorigenesis. **Nat Genet**. 2014 Jan;46(1):33-8.
- Wyspiańska BS... Nangalia J... Kouzarides T. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. **Leukemia**. 2014 Jan;28(1):88-97.
- Aziz A, Baxter EJ, Edwards C...Nangalia J...Green AR. Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. **J Clin Invest**. 2013 May 1;123(5):2169-82.
- Broseus J, Florensa L, Zipperer E... Evans J... Girodon F. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. **Haematologica**. 2012 Jul;97(7):1036-41.
- Li W, Adams TE, Nangalia J... Huntington JA. Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-Å structure of the heparin-bridged complex. **Proc Natl Acad Sci U S A**. 2008 Mar 25;105(12):4661-6.